Market Overview

D.A. Davidson Expects Long-Term Success For Nautilus


In a report published Tuesday, D.A. Davidson analyst Andrew Burns reiterated a Buy rating and $18.00 price target on Nautilus, Inc. (NYSE: NLS).

In the report, D.A. Davidson noted, “We expect a positive 4Q with continued momentum into 2015. In recent weeks we hosted investor meetings with NLS management and studied the exercise equipment retail landscape to gauge the traction of NLS' new and existing product lines. We are encouraged by management's strong execution and long-term growth vision. On the retail front, our checks show continued strength of the Schwinn cardio line and broad availability of the new Nautilus line across most key retailer ecommerce platforms. We believe both the direct and retail segments will perform during the important 4Q-1Q sales period. Similar to the last two years, Nautilus should provide a favorable business update on 4Q trends at the upcoming ICR XChange conference (Jan. 12th-14th).”

Nautilus closed on Monday at $14.87.

Latest Ratings for NLS

Jul 2019UpgradesIn-LineOutperform
Feb 2019DowngradesBuyHold
Jan 2019DowngradesBuyNeutral

View More Analyst Ratings for NLS
View the Latest Analyst Ratings

Posted-In: Andrew Burns D.A. DavidsonAnalyst Color Reiteration Analyst Ratings


Related Articles (NLS)

View Comments and Join the Discussion!

Latest Ratings

HSKACanaccord GenuityMaintains75.0
AVGOMorgan StanleyMaintains265.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Bank Of America: Macau's Gross Gaming Revenue Improved, Highlights Other News Developments

Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject Injection